Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167

Watchlist Manager
Jacobio Pharmaceuticals Group Co Ltd Logo
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Watchlist
Price: 7.8 HKD 7.59% Market Closed
Market Cap: 6.2B HKD

EV/EBITDA
Enterprise Value to EBITDA

-26
Current
-4.1
Median
5.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-26
=
Enterprise Value
5B HKD
/
EBITDA
-177.7m CNY
EBITDA Growth EV/EBITDA to Growth
CN
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Average EV/EBITDA: 16.2
Negative Multiple: -26
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 117.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.8
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.4
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
11
6%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.5
17%
1.2
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
9%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -443.2 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-25
2-Years Forward
EV/EBITDA
-21.3
3-Years Forward
EV/EBITDA
-32.9